Journal
BLOOD
Volume 135, Issue 20, Pages 1725-1726Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood.2020005720
Keywords
-
Categories
Ask authors/readers for more resources
In this issue of Blood, Zambetti et al validate that palmitoylation of mutant NRAS is essential for its oncogenic function by using a genetic mouse model. Their study highlights that the palmitoylation/depalmitoylation cycle is an attractive candidate for therapeutic intervention in hematologic malignancies with NRAS mutations.(1)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available